Alvotech (ALVO) EV/FCF: History & Chart

Alvotech(ALVO)

Drug Manufacturers - Specialty & Generic · Luxembourg, LU

$6.03-0.08 (-1.33%)

Delayed quote: Oct 6, 2026, 9:34 AM EDT

About Alvotech

Alvotech, along with its various subsidiaries, is dedicated to the global development and manufacturing of biosimilar pharmaceuticals. Its product offerings span key therapeutic categories, encompassing autoimmune conditions, eye disorders, bone diseases, and cancer. A flagship program for the company is AVT02, a high-concentration biosimilar equivalent to Humira. This candidate is designed to address a range of inflammatory illnesses, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, and plaque psoriasis. Similarly, AVT04 is a biosimilar version of Stelara, targeting inflammatory conditions such as psoriatic arthritis, Crohn's disease, ulcerative colitis, and plaque psoriasis. For ophthalmic conditions, AVT06 serves as a biosimilar to Eylea, intended for the treatment of age-related macular degeneration, macular edema, and diabetic retinopathy. Currently in preclinical stages, AVT03 is a biosimilar to Xgeva and Prolia, with the goal of preventing bone fractures, alleviating spinal cord compression, reducing the necessity for radiation or bone surgery in certain cancer patients, and both preventing bone loss and increasing bone density. Additionally, Alvotech's pipeline features AVT05, an early-stage biosimilar for Simponi and Simponi Aria, which is being developed for various inflammatory conditions like rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis. Other promising candidates include AVT16, an immunology biosimilar; AVT23, a late-stage biosimilar to Xolair, aimed at treating nasal polyps; and AVT33, an oncology biosimilar. Established in 2013, Alvotech maintains its primary corporate headquarters in Reykjavik, Iceland.

Luxembourg, LU

1,279 employees

www.alvotech.com

Healthcare / Drug Manufacturers - Specialty & Generic

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
CEO: Lisa Graver

View full financials

NAME	MARKET CAP	EV/FCF RATIO	TTM	3Y	5Y
Alvotech (ALVO)	$2.04B	N/A	N/A	N/A	N/A
Azenta, Inc. (AZTA)vs ›	$2.05B	193.34x	49.00x	83.04x	82.00x
BioCryst Pharmaceuticals, Inc. (BCRX)vs ›	$2.05B	6.45x	31.04x	48.35x	48.35x
Aurinia Pharmaceuticals Inc. (AUPH)vs ›	$2.02B	10.97x	15.23x	21.85x	21.85x
AxoGen, Inc. (AXGN)vs ›	$2.02B	769.26x	495.80x	11749.41x	11749.41x
Inspire Medical Systems, Inc. (INSP)vs ›	$2.07B	16.82x	20.29x	742.45x	860.87x
Absci Corporation (ABSI)vs ›	$1.99B	N/A	N/A	N/A	N/A
Immunome, Inc. (IMNM)vs ›	$1.99B	N/A	28.11x	28.11x	28.11x
Establishment Labs Holdings Inc. (ESTA)vs ›	$1.99B	N/A	N/A	N/A	N/A
Addus HomeCare Corporation (ADUS)vs ›	$2.12B	13.94x	18.28x	18.51x	20.32x

NAME

MARKET CAP

EV/FCF RATIO

TTM

Alvotech (ALVO)

$2.04B

N/A

Azenta, Inc. (AZTA)vs ›

$2.05B

193.34x

49.00x

83.04x